BXP — Beximco Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSuper Stock

Annual income statement for Beximco Pharmaceuticals, fiscal year end - June 30th, BDT millions except per share, conversion factor applied.

	2021 June 30th	2022 June 30th	2023 June 30th	2024 June 30th	2025 June 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	BAS	BAS	BAS	BAS	BAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	29,494	34,669	39,267	44,392	49,120
Cost of Revenue
Gross Profit	13,924	15,814	17,313	19,634	22,296
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	22,843	27,768	32,050	35,717	39,273
Operating Profit	6,651	6,901	7,216	8,674	9,848
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	6,378	6,687	6,069	7,525	9,004
Provision for Income Taxes
Net Income After Taxes	5,166	4,999	4,524	5,867	6,999
Minority Interest
Net Income Before Extraordinary Items
Net Income	5,128	5,123	4,614	5,830	6,941
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	5,128	5,123	4,614	5,830	6,941
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	11.5	11.6	10.3	13	15.5
Dividends per Share